Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuraxis (NRXS) EBIT (2022 - 2025)

Neuraxis (NRXS) has disclosed EBIT for 4 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 17.07% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.8 million through Dec 2025, down 9.4% year-over-year, with the annual reading at -$7.8 million for FY2025, 9.4% down from the prior year.
  • EBIT hit -$1.7 million in Q4 2025 for Neuraxis, up from -$2.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$669582.0 in Q2 2022 to a low of -$3.0 million in Q3 2023.
  • Historically, EBIT has averaged -$1.6 million across 4 years, with a median of -$1.7 million in 2024.
  • Biggest five-year swings in EBIT: plummeted 151.21% in 2023 and later soared 45.36% in 2024.
  • Year by year, EBIT stood at -$986226.0 in 2022, then crashed by 64.59% to -$1.6 million in 2023, then increased by 9.65% to -$1.5 million in 2024, then dropped by 17.07% to -$1.7 million in 2025.
  • Business Quant data shows EBIT for NRXS at -$1.7 million in Q4 2025, -$2.1 million in Q3 2025, and -$1.7 million in Q2 2025.